Stallergenes Greer plc, a biopharmaceutical company specializing in treatments for respiratory allergies, will today host an Innovation Day for analysts and investors from 10:00am BST to 12.15pm BST at its headquarters, 40 Bernard Street, Bloomsbury, London WC1N 1LE.
The event will include presentations, providing a more detailed understanding of Stallergenes Greer's strategy and innovation, followed by a question and answer session. The company will notably present real-world evidence data about ORALAIR® and its strategic investment in Adeo Health Science, announced today.
The company will host a live webcast on Stallergenes Greer’s website available in the investor section at www.stallergenesgreer.com (http://edge.media-server.com/m6/go/STAGR_ID2017). Those attending via webcast will have the opportunity to submit questions, via the webcast tool, following the presentations.
Relevant documents and materials related to the Innovation Day will be available from the company website shortly after the event has concluded.
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of Greer Laboratories, Inc. (whose registered office is in the US) and Stallergenes SAS (whose registered office is in France).
Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR - ICB Classification: 4577
Market: Euronext Paris regulated market
Additional information is available at http://www.stallergenesgreer.com.
This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe," "expects," "project," "estimated," "forecast," "should," "plan," "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2016 annual report published on 28 April 2017 on the Company's website www.stallergenesgreer.com. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.
Communications and Investor Relations
Natacha Gassenbach, +1 617-225 8013
Investor Relations Agency
Arnaud de Cheffontaines, +33 1 47 03 68 10
Media Relations Agency
Havas Worldwide Paris (Europe)
Samuel Rousseau, +33 (0) 6 51 03 51 43
Serra Saridereli, +1 212-715 1604
Classification : Additional regulated information required to be disclosed under the laws of a Member State